目的 探讨正心泰颗粒联合盐酸贝尼地平片治疗冠心病心绞痛的疗效。方法 选取河北港口集团有限公司秦皇岛中西医结合医院在2024年2月到2025年1月收治的138例冠心病心绞痛患者，按随机数字表法将所有患者分为对照组和治疗组，各组包括69例。对照组口服盐酸贝尼地平片，1次/d，2片/次。治疗组患者在对照组基础上冲服正心泰颗粒，3次/d，1袋/次。两组持续完成1个月的治疗。比较两组患者的治疗效果、心绞痛疼痛程度、心绞痛频次和持续时间、生活质量、心功能指标、血清指标。结果 对照组的总有效率为81.16%，治疗组的总有效率为92.75%，组间差异显著（P＜0.05）。两组治疗后的心绞痛频次、持续时间、视觉模拟量表（VAS）评分明显减轻（P＜0.05），且治疗组治疗后心绞痛频次、持续时间、VAS评分均低于对照组（P＜0.05）。治疗后，两组西雅图心绞痛量表（SAQ）评分均显著提高（P＜0.05），治疗组治疗后SAQ评分明显高于对照组（P＜0.05）。治疗后，两组的左心室射血分数、短轴缩短率、心输出量均升高（P＜0.05），且治疗组的左心室射血分数、短轴缩短率、心输出量比对照组更高（P＜0.05）。两组患者治疗后血清心型脂肪酸结合蛋白（H-FABP）、T细胞免疫球蛋白黏蛋白分子3（Tim3）、Clq肿瘤坏死因子相关蛋白1（CTRP1）水平均明显降低（P＜0.05），治疗组治疗后血清H-FABP、Tim3、CTRP1水平明显低于对照组（P＜0.05）。结论 正心泰颗粒联合盐酸贝尼地平片可提高冠心病心绞痛的疗效，减轻心绞痛症状，改善生活质量，减轻炎症反应，提高心功能。

Objective To explore the therapeutic effect of Zhengxintai Granules combined with Benazepril Hydrochloride Tablets in treatment of angina pectoris in coronary heart disease. Methods 138 Patients with coronary heart disease angina admitted to Hebei Port Group Co., Ltd. Qinhuangdao Integrated Traditional Chinese and Western Medicine Hospital from February 2024 to January 2025 were selected and were divided into control group and treatment group using a random number table method, with 69 cases in each group. The control group of patients took orally Beninidipine Hydrochloride Tablets, 2 tablets each time, once daily. Patients in the treatment group were po administered with Zhengxintai Granules on the basis of the control group, 3 times daily, 1 bag per time. Two groups completed 1 month of treatment continuously. The treatment efficacy, degree of angina pain, frequency and duration of angina, quality of life, cardiac function indicators, and serum indicators were compared between two groups of patients. Results The total effective rate of the control group was 81.16%, while the total effective rate of the treatment group was 92.75%, and the difference between the groups was significant (P < 0.05). The frequency, duration, and visual analog scale (VAS) scores of angina pectoris in both groups were significantly reduced after treatment (P < 0.05), and the frequency, duration, and VAS scores of the treatment group were lower than those of the control group after treatment (P < 0.05). After treatment, the Seattle Angina Questionnaire (SAQ) scores in two groups were significantly increased (P < 0.05), and the SAQ scores in the treatment group were higher than those in the control group (P < 0.05). After treatment, the left ventricular ejection fraction, short axis shortening rate, and cardiac output of two groups were increased (P < 0.05), and the left ventricular ejection fraction, short axis shortening rate, and cardiac output of the treatment group were higher than those of the control group (P < 0.05). After treatment, the serum levels of heart type fatty acid binding protein (H-FABP), T cell immunoglobulin mucin molecule 3 (Tim3), and Clq tumor necrosis factor related protein 1 (CTRP1) in two groups of patients were significantly decreased (P < 0.0), and the serum levels of H-FABP, Tim3, and CTRP1 in the treatment group were significantly lower than those in the control group after treatment (P < 0.05). Conclusion The combination of Zhengxintai Granules and Benazepril Hydrochloride Tablets can improve the efficacy of angina pectoris in coronary heart disease, alleviate angina symptoms, improve quality of life, alleviate inflammatory reactions, and enhance cardiac function.

R972

秦皇岛市科学技术研究与发展计划（202301A078）